WO2001043692A2 - SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID - Google Patents
SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID Download PDFInfo
- Publication number
- WO2001043692A2 WO2001043692A2 PCT/US2000/033966 US0033966W WO0143692A2 WO 2001043692 A2 WO2001043692 A2 WO 2001043692A2 US 0033966 W US0033966 W US 0033966W WO 0143692 A2 WO0143692 A2 WO 0143692A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclopentyloxy
- cyano
- methoxyphenyl
- cyclohexane
- carboxylic acid
- Prior art date
Links
- CFBUZOUXXHZCFB-UHFFFAOYSA-N COc1ccc(C(CC2)(CCC2C(O)=O)C#N)cc1OC1CCCC1 Chemical compound COc1ccc(C(CC2)(CCC2C(O)=O)C#N)cc1OC1CCCC1 CFBUZOUXXHZCFB-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N NC(CO)(CO)CO Chemical compound NC(CO)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/09—Diamines
- C07C211/10—Diaminoethanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- This invention relates to certain salts of a carboxylic acid useful for treating diseases treatable by inhibiting the PDE4 enzyme.
- Cyclic nucleotide phosphodiesterases represent a family of enzymes that hydrolyze the ubiquitous intracellular second messengers, adenosine 3 ',5 '-monophosphate (cAMP) and guanosine 3 ',5 '-monophosphate (cGMP) to their corresponding inactive 5 - monophosphate metabolites.
- PDE isozymes At least ten distinct classes of PDE isozymes are believed to exist, each possessing unique physical and kinetic characteristics and each representing a product of a different gene family. These are distinguished using Arabic numerals 1 - 10.
- PDE inhibitors used in treating inflammation and as bronchodilators drugs like theophylline and pentoxyfyllin, inhibit PDE isozymes indiscriminately in all tissues. These compounds exhibit side effects, apparently because they non-selectively inhibit all PDE isozyme classes in all tissues.
- the targeted disease state may be effectively treated by such compounds, but unwanted secondary effects may be exhibited which, if they could be avoided or minimized, would increase the overall therapeutic effect of this approach to treating certain disease states.
- a new approach toward improving the side effect profile of PDE inhibitors is to design a new generation of compounds that inhibit only a single PDE isozyme, i.e., the PDE isozyme that predominates in the tissue of cell of interest.
- the predominate cAMP PDE isozyme in immune and inflammatory cells is PDE4. It is also a major regulator of cAMP content in airway smooth muscle.
- selective inhibition of PdE4 elevates cAMP content in immune and inflammatory cells, as well as in airway smooth muscle. This leads to anti-inflammatory effects as well as bronchodilation.
- One or both of these therapeutic actions are useful in treating a variety of diseases, including, but not limited to asthma and COPD.
- PDE4 inhibitors particularly PDE4-specific inhibitors are useful also in treating other diseases in the area of inflammation, (e.g., asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, rheumatoid arthritis), affects related to tumor necrosis factor and to cognition impairment (e.g., multi-infarct dementia, cognitive dysfunction, or stroke).
- diseases in the area of inflammation e.g., asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, rheumatoid arthritis
- cognition impairment e.g., multi-infarct dementia, cognitive dysfunction, or stroke.
- isozyme-selective PDE inhibitors should represent an improvement over non-selective inhibitors, the selective inhibitors tested to date are not devoid of side effects produced as an extension of inhibiting the isozyme of interest in an inappropriate or untargeted tissue, or because they may have cross-reactivity with other PDE isozymes.
- This invention relates to the following salts of * -4-cyano-4-[3- (cyclopentyloxy)- 4-methoxyphenyl]cyclohexane-l-carboxylic acid: sodium, ethylene diamine and tris(hydroxymethy)aminomethane.
- Salts of this acid were prepared and characterized as per the following examples.
- DSC indicated three small endotherms at 154.4 °C, 185.1 °C and 212.0 °C, one major endotherm at 230 °C and probable decomposition at 324.3 °C
- DSC showed two small endotherms at 162.1 °C and 189.2 °C and one major endotherm at 232.7 °C, followed by probable decomposition at 333.0 °C.
- the resulting solution was kept at 60 °C for 15 minutes.
- the mixture was allowed to cool to 45 °C over 20 minutes and seeded with 2 mg of seed crystal. In few second the salt started to precipitate.
- the cooling was continued to room temperature then to 0 °C over 45 minutes.
- the suspension was stirred at 0 °C for additional 2 hours then was filtered through sintered funnel.
- the filter cake was rinsed with 2 X 2.0 ml cold isopropanol.
- the product was dried under Hi-Nac for 20 hours to a constant weight.
- ⁇ ⁇ MR was satisfactory; M. P. : 158-161 °C; Karl Fisher : 0.15 %; DSC one small endotherm at 77.4 °C , one major at 167.4 °C and probable decomposition at >180 °C; IR(KBr): 3379, 2959, 2860, 2638, 2229, 1617, 1519, 1414, 1268, 1234, 1148, 1024, 988, 936, 807, 739, 634 cm " 1 .
- the solution was cooled to room temperature then further chilled to 0 °C in an ice water bath for 1.0 h.
- the solid was isolated by filtration and the filter cake was rinsed with 2X2.0 ml isopropanol.
- the product was dried under Hi-vac at room temperature for 20 h or to constant weight.
- tris(hydroxymethyl)aminomethane (1.10 g (9.091 mmoles, 1.04 equivalents) was added in a mixture of 8.0 ml of MeOH and 1.0 ml of deionized water. Some heating was required to obtain a clear solution of the amine. The resulting clear solution was stirred and cooled to room temperature for 2.0 hours without precipitation. Upon stirring overnight (16 hours) at room temperature, heavy precipitation formed. The slurry was diluted with 15 ml of isopropanol, then was transferred to a sintered funnel under vacuum. The filter cake was rinsed with 2 X 5.0 ml of cold isopropanol (0-5 °C). The product was dried under Hi-vac for 72 hours.
- DSC indicated one sharp major endotherm at 147.1 °C and one shoulder at 153.2 °C.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00989266A EP1237851A4 (en) | 1999-12-15 | 2000-12-15 | SALTS OF i Cis /i -4-CYANO-4- 3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID |
JP2001544633A JP2003534238A (en) | 1999-12-15 | 2000-12-15 | Salt of cis-4-cyano-4- [3- (cyclopentyloxy) -4-methoxyphenyl] cyclohexane-1-carboxylic acid. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17097799P | 1999-12-15 | 1999-12-15 | |
US60/170,977 | 1999-12-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001043692A2 true WO2001043692A2 (en) | 2001-06-21 |
WO2001043692A3 WO2001043692A3 (en) | 2002-03-07 |
Family
ID=22622045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/033966 WO2001043692A2 (en) | 1999-12-15 | 2000-12-15 | SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1237851A4 (en) |
JP (1) | JP2003534238A (en) |
WO (1) | WO2001043692A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1194142A1 (en) * | 1999-05-25 | 2002-04-10 | SmithKline Beecham Corporation | Salts of cis -4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl) cyclohexan-1-carboxylate! |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2746316C (en) * | 2008-12-08 | 2017-01-03 | Glaxosmithkline Llc | Tris(hydroxymethyl)aminomethane salt of 8-chloro-3-pentyl-3,7-dihydro-1h-purine-2,6 dione and its use in therapy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999034798A1 (en) * | 1998-01-07 | 1999-07-15 | Smithkline Beecham Corporation | Method for treating copd |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA67753C2 (en) * | 1997-10-10 | 2004-07-15 | Смітклайн Бічам Корпорейшн | Method for obtaining substituted of cyanocyclohexan acid |
AR024076A1 (en) * | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | CIS- [4-CIANO-4- (3-CICLOPENTILOXI-4-METOXIFENIL) CICLOHEXAN-1-CARBOXYLATE SALTS] |
-
2000
- 2000-12-15 JP JP2001544633A patent/JP2003534238A/en not_active Withdrawn
- 2000-12-15 WO PCT/US2000/033966 patent/WO2001043692A2/en not_active Application Discontinuation
- 2000-12-15 EP EP00989266A patent/EP1237851A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999034798A1 (en) * | 1998-01-07 | 1999-07-15 | Smithkline Beecham Corporation | Method for treating copd |
Non-Patent Citations (1)
Title |
---|
See also references of EP1237851A2 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1194142A1 (en) * | 1999-05-25 | 2002-04-10 | SmithKline Beecham Corporation | Salts of cis -4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl) cyclohexan-1-carboxylate! |
EP1194142A4 (en) * | 1999-05-25 | 2002-10-25 | Smithkline Beecham Corp | Salts of cis -4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl) cyclohexan-1-carboxylate! |
Also Published As
Publication number | Publication date |
---|---|
EP1237851A4 (en) | 2004-06-23 |
JP2003534238A (en) | 2003-11-18 |
EP1237851A2 (en) | 2002-09-11 |
WO2001043692A3 (en) | 2002-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5226018B2 (en) | Pyrrotriazine aniline compounds useful as kinase inhibitors | |
US7317016B2 (en) | Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives | |
US6384236B1 (en) | N-(aroyl)glycine hydroxamic acid derivatives and related compounds | |
EP1165558B1 (en) | Derivatives of pyrimido[6,1-a]isoquinolin-4-one | |
KR100673638B1 (en) | Aryl alkanoylpyridazines | |
WO1996021435A1 (en) | Compounds for and method of inhibiting phosphodiesterase iv | |
US6303613B1 (en) | Aminopyrimidine derivatives, processes for their preparation, compositions containing them and their use as pharmaceuticals | |
EP0007206B1 (en) | Phenethanolamines, their formulations, preparation and use | |
CN101124229B (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders | |
CN100402515C (en) | Substituted phthalides as anti-convulsive drugs | |
US5840979A (en) | Aliphatic propargylamines as cellular rescue agents | |
KR20180100225A (en) | 7H-pyrrolo [2,3-d] pyrimidine compound | |
WO2001043692A2 (en) | SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID | |
JP2001512724A (en) | α1a adrenergic receptor antagonist | |
US20030013905A1 (en) | Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid | |
RU2156252C2 (en) | Triazolopyridazines, method of their synthesis, pharmaceutical compositions based on thereof and method of treatment | |
US20070270446A1 (en) | Reversed Pyrimidinone Compounds as Calcilytics | |
AU596927B2 (en) | Pyrido (1,8) naphthyridinones and their use as pharmaceuticals | |
TW200812942A (en) | Non-nucleoside reverse transcriptase inhibitors | |
EP0570401A1 (en) | Lipoxygenase-inhibiting hydroxamic acid and n-hydroxyurea derivatives. | |
WO2000071114A1 (en) | Salts of cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-carboxylate] | |
JP2006515018A (en) | Pyrido [2,3-d] pyrimidine-7-carboxylic acid derivatives, their production and use as pharmaceutical agents | |
JPH07508045A (en) | Ornithine decarboxylase inhibitory cyclic aminooxy compounds | |
JPS61158944A (en) | 9-aminoalkylfluorenes | |
OA11370A (en) | Process for the synthesis of chloropurine intermediates. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 544633 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10149524 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000989266 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000989266 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000989266 Country of ref document: EP |